Avicanna Announces Appointment of Paul Fornazzari to Board of Directors
13 Novembre 2023 - 11:30PM
Avicanna Inc. (“
Avicanna” or the
“
Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a
biopharmaceutical company focused on the commercialization of
proprietary cannabinoid-based products and a medical cannabis care
platform is pleased to announce the appointment of Paul Fornazzari
to the board of directors.
Paul Fornazzari is a business executive,
securities lawyer, and board director with over twenty-five years
of experience with growth-stage and established Canadian and
international companies. Mr. Fornazzari is also a Partner focusing
on Securities and Corporate Finance with Fasken Martineau DuMoulin
(“Fasken”) one of Canada’s largest law firms with a well recognized
domestic and international practice. In addition to English, Mr.
Fornazzari is a fluent Spanish speaker from Latin America.
“I am excited to be joining the Board of
Directors” said Paul Fornazzari, and further said “as a long-time
shareholder, I believe in the Company’s management and in the
Company’s business model, I have been excited over the Company’s
recent developments, and I look forward to contributing towards the
Company’s future as the Avicanna team aims and works to grow the
business.”
“We are thrilled to add Mr. Fornazzari to our
board of directors, where his expertise and experience with
successful entrepreneurial projects will support the further growth
of the Company,” stated Aras Azadian, CEO.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
- Medical Cannabis &
Wellness Products (RHO
Phyto™): The
formulary offers a diverse range of proprietary formulations
including oral, sublingual, topical, and transdermal deliveries
with varying ratios of cannabinoids and is supported with ongoing
patient, and medical community education. RHO Phyto has been
established as a leading medical brand in Canada and is currently
available nationwide to patients across several medical channels
and continues to expand into new international markets.
- Pharmaceutical Preparations
and Pipeline: Leveraging Avicanna’s
scientific platform, vertical integration, and real-world evidence,
Avicanna has developed an extensive a pipeline of patent-pending
drug candidates that are indication-specific and in various stages
of clinical development and commercialization. These
cannabinoid-based drug candidates look to address unmet medical
needs in the areas of dermatology, chronic pain, and various
neurological disorders. Avicanna’s first pharmaceutical preparation
(Trunerox™) is in the drug registration stage in South
America.
- MyMedi.ca
Medical Cannabis Care: MyMedi.ca
is Avicanna’s medical cannabis care platform that is formed with
the aim to better serve medical cannabis patients’ needs and
enhance the patient journey. MyMedi.ca features diverse and
scientifically curated products from leading Canadian licensed
producers in addition to pharmacist led patient support programs
and educational resources to facilitate the incorporation of
medical cannabis into health care regimens. MyMedi.ca also provides
specialty services to distinct patient groups such as veterans and
collaborating with public and private providers for adjudication
and reimbursement.
Click to watch Avicanna’s Corporate Video
2022
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit our
website, contact Ivana Maric by email at info@avicanna.com or
follow us on social media
on LinkedIn, Twitter, Facebook, or Instagram.
The Company posts updates through videos from
the Company YouTube channel.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified using words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
March 31, 2023 filed with the Canadian securities regulators and
available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024